Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:SOLARA

SOLARA ACTIVE PHA SCI LTD

Healthcare › Pharmaceuticals & Biotechnology
₹753.00
at close · 21 Sept 2026
▲ 10.95 (+1.48%)

Latest filings

  1. Solara Active Pharma: 9th AGM held; 5 resolutions passed including Rs 480 cr RPT with Strides · Board & Shareholder Meetings
  2. Income tax demand of Rs. 161.92 Cr dropped via Rectification Order · Regulatory & Legal
  3. Solara Active 9th AGM notice and annual report dispatch completed · Compliance
  4. Solara files FY2025-26 BRSR with stronger renewable energy use · Compliance
  5. Notice of 9th AGM and Annual Report FY2025-26 · Board & Shareholder Meetings
  6. AGM notice dispatched for September 18, 2026 - FY26 accounts and Strides RPT on agenda · Board & Shareholder Meetings
  7. Notice of 9th AGM on September 18, 2026 via video conferencing · Compliance
  8. Solara converts 2.79 lakh partly paid rights shares to fully paid-up · Fund Raising
  9. Allotment of 2,250 equity shares under ESOP 2018 · Capital Market Events
  10. CIO joining date revised to August 17, 2026 · Management Changes
  11. Solara Q1 FY27: Revenue up 20%, PAT up 55% YoY; net debt down 22% · Investor Communications
  12. Newspaper publication of Q1 FY27 financial results · Compliance
  13. Solara Active Pharma Q1 FY27 Results: Revenue up 19.6%, Profit up 55% YoY · Compliance
  14. Solara Active Pharma uploads Q1 FY27 earnings call audio recording · Investor Communications
  15. Rights Issue monitoring report Q1 FY27 - no deviations noted · Compliance
  16. No deviation in Rights Issue fund use for Q1FY27 · Compliance
  17. Allotment of 2,250 shares under ESOP Plan 2018 · Capital Market Events
  18. Solara appoints Ajit Manocha as Chief Information Officer · Management Changes
  19. Solara Q1 FY27: highest EBITDA and PAT in 18 quarters · Compliance
  20. Solara Q1 FY27: Highest EBITDA and PAT in 18 quarters; Revenue up 20% YoY · Compliance
  21. Solara Active Pharma Q1 FY27 profit up 55% YoY at Rs 16.31 Cr · Results
  22. Solara Active Pharma Q1 FY27: PAT jumps 55% YoY to Rs 16.31 Cr · Results
  23. Solara Active Pharma Q1 FY27 PAT up 55% YoY at Rs 16.31 cr · Results
  24. Investors/Analysts call on July 23, 2026 for Q1FY27 results · Board & Shareholder Meetings
  25. Board meeting on July 23 to consider Q1 FY27 results · Results
  26. Final reminder for call money payment; share forfeiture risk · Compliance
  27. Quarterly compliance certificate for dematerialisation of securities · Compliance
  28. Final Reminder-cum-Forfeiture Notice for unpaid rights call money · Corporate Actions
  29. Transfer of unclaimed shares to IEPF Authority · Compliance
  30. Transfer of shares to IEPF for unclaimed FY2018-19 dividend · Compliance
  31. Solara sending IEPF transfer notices for FY19 unclaimed dividend shares · Compliance
  32. Trading window closure from July 1, 2026 for Q1 results · Compliance
  33. CRISIL upgrades Solara Pharma credit rating to BBB+/Stable · Credit & Debt
  34. Solara Active Pharma allots 70,000 shares under ESOP 2024 · Capital Market Events
  35. Allotment of 2,250 equity shares under ESOP 2018 · Capital Market Events
  36. Significant increase in volume has been observed in Solara Active Pharma Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Solara Active Pharma Sciences Limited has submitted their response. · Regulatory & Legal
  37. Significant increase in volume has been observed in Solara Active Pharma Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. · Regulatory & Legal
  38. SOLARA: Solara Active Pharma Sciences Limited has informed the exchange regarding the Special window for Transfer and Dematerialisation of shares · Compliance
  39. Solara Active Pharma Sciences Limited has informed the exchange regarding the submission of Annual Secretarial Compliance Report for the fInancial year ended March 31, 2026 · Compliance
  40. Pronomz Ventures LLP has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 · Ownership Changes
  41. Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of earnings conference call pertaining to financial results of the Company for the quarter and year ended March 31, 2026. · Investor Communications
  42. Transcript of Earnings conference call pertaining to financial results of the Company for the quarter and year ended March 31, 2026 · Investor Communications
  43. Copy of newspaper publication in relation to the financial results for the quarter and year ended March 31, 2026 · Compliance
  44. Copy of newspaper publication with respect to financial results for the quarter and year ended March 31, 2026 · Compliance
  45. Solara Active Pharma Sciences Limited has intimated the Exchange about the Audio Recording of the Q4 FY26 Earnings Call held on May 15, 2026 at 15.00 IST. · Investor Communications
  46. Solara Active Pharma Sciences Limited has intimated the Exchange about the Audio Recording of the Q4 FY26 Earnings Call held on May 15, 2026, at 15.00 IST. · Investor Communications
  47. Monitoring Agency Report for the quarter ended March 31, 2026 · Compliance
  48. Monitoring Agency Report for the quarter ended March 31, 2026 · Compliance
  49. Solara Active Pharma Sciences Limited has informed the exchange regarding the approval and adoption of the Board Evaluation Policy and amendment to Whistle Blower Policy · General
  50. Solara Active Pharma Sciences Limited has informed the exchange regarding the approval and adoption of Board Evaluation policy and amendment to Whistle Blower Policy. · General
All filings ↓
Ask Nexa about SOLARA ACTIVE PHA SCI LTD

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Manufactures active pharmaceutical ingredients (APIs), reporting Q1 FY27 revenue of INR 384 cr (+20% YoY) and EBITDA of INR 63.5 cr. The business is described in two parts: a "base business" of non-Ibuprofen APIs that posted INR 307 cr of revenue (+24% YoY) with INR 72 cr of EBITDA (+8% YoY), and an Ibuprofen commodity business running at -12% EBITDA margin with an EBITDA loss of INR 87 mn in the quarter and under strategic review targeted for resolution by H1 FY27. Management has guided the base business to 25% plus/minus 1% EBITDA margin and 52-55% gross margin, with FY27 capex of INR 55-60 cr going entirely to maintenance and debottlenecking (20-30% capacity uplift, no greenfield). Raw materials are the largest cost at 49.1% of FY26 revenue, with the West Asia crisis cited as a current input-cost and supply headwind. Net debt stood at INR 479 cr at end-June 2026 (1.9x EBITDA), reduced by ~INR 135 cr in the quarter via rights-issue call money and operating cash flow, with the company also progressing a CRAMS and Polymers demerger into a separate listed entity.

Operating scale
Q1 FY27 consolidated revenue
INR 384 cr (+20% YoY)Q1 FY27
Q1 FY27 base business revenue
INR 307 cr (+24% YoY)Q1 FY27
Q1 FY27 Ibuprofen EBITDA
INR 87 mn lossQ1 FY27
Net debt
INR 479 cr (1.9x EBITDA)as of 30 June 2026
FY27 capex guidance
INR 55-60 cr (maintenance + debottlenecking only)FY27
Raw materials as % of revenue
49.1%FY26
Biggest cost
Raw materials at 49.1% of FY26 revenue, with API starting materials exposed to West Asia-related price and supply pressure
Kind of business
API manufacturer; asset-heavy, currently deleveraging with Ibuprofen business under strategic review and CRAMS/Polymers demerger in progress
Where it sits
Q1 FY27 EBITDA and PAT were the highest in 18 quarters; net debt cut by ~22% QoQ; CRISIL upgraded long-term rating to BBB+/Stable
Market Cap
₹3,619 Cr
P / E (TTM)
—
EV / EBITDA
22.1×
Div Yield
—
Growth
-3.3%▼
Revenue 5y CAGR
PAT — · EBITDA -14.7%
Quality
2.5%·
ROCE (5y median)
ROE -1.5% · margin 13.7%
Leverage
0.53·
Debt / Equity · moderate
Net debt ₹660 Cr
Revenue FY21→FY26
0.8×▼
Margin −14.2 pts
₹1,617 Cr → ₹1,369 Cr
Moves on a normal day
1.28%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/B#76/164
ROCE#154/183
ROE#148/171
Debt / Equity#143/171
EBITDA margin#84/165
Revenue growth#72/161
Profit growth#61/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Nothing stands out in the filed numbers.
Concerns
Slow revenue growth — -3% a year over 5 years
Erratic profits — up in only 2 of the last 5 years
Returns on capital 2.5% (5-year median)
#154 of 183 in Pharmaceuticals on the latest reported figures · down from 16.8% in FY21
Carries more debt than its peers — 0.53× equity
lower than 17% of its 171 Pharmaceuticals peers
Heavy working capital — 129 days of cash tied up

Charts

How has the market priced it — with filings on the timeline?

SOLARA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from SOLARA ACTIVE PHA SCI LTD's filed financials and exchange disclosures

What does SOLARA ACTIVE PHA SCI LTD do?

SOLARA ACTIVE PHA SCI LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SOLARA.

Is SOLARA ACTIVE PHA SCI LTD profitable?

No. Over the trailing twelve months SOLARA ACTIVE PHA SCI LTD reported a net loss of ₹2 Cr on revenue of ₹1,431 Cr.

Does SOLARA ACTIVE PHA SCI LTD pay a dividend?

Not in the latest reported year — SOLARA ACTIVE PHA SCI LTD's dividend payout for FY26 was nil.

Is SOLARA ACTIVE PHA SCI LTD debt-free?

No. Debt stands at 0.53× equity, and it carries net debt of ₹660 Cr. That is lower than 17% of its 171 Pharmaceuticals peers.

How much does the SOLARA ACTIVE PHA SCI LTD share price move in a day?

On a typical session SOLARA ACTIVE PHA SCI LTD moves 1.28% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.

Where can I track SOLARA ACTIVE PHA SCI LTD's announcements?

Every NSE and BSE filing by SOLARA ACTIVE PHA SCI LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.